Tier 1 — highest

Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials

Vahidreza Ostadmohammadi, Alireza Milajerdi, Elnaz Ayati, Fariba Kolahdooz, Zatollah Asemi
Phytotherapy research : PTR 2019 33(5):1330-1340

Bibliography

PubMed
PMID 30848564
DOI
10.1002/ptr.6334
Funding
Indexed grant support: Research Deputy of Kashan University of Medical Sciences (KAUMS). The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of randomized trials
ModelHuman evidence synthesis
Sample9 studies contributing 10 effect sizes
InterventionQuercetin in metabolic syndrome and related disorders
DurationSearches through August 30, 2018
EndpointsGlucose and insulin measures

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Its evidence base was 9 studies contributing 10 effect sizes. It evaluated Quercetin in metabolic syndrome and related disorders across Searches through August 30, 2018.

Overall fasting glucose, insulin resistance, and HbA1c did not improve; selected dose or duration subgroups showed favorable findings.

Subgroup signals do not establish an overall glucose-lowering treatment effect or prevention of diabetes complications.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Overall fasting glucose, insulin resistance, and HbA1c did not improve; selected dose or duration subgroups showed favorable findings.
  • The recorded outcome domains were Glucose and insulin measures.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Subgroup signals do not establish an overall glucose-lowering treatment effect or prevention of diabetes complications.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 1
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Reza Tabrizi et al. · Critical reviews in food science and nutrition · 2020

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology